Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration

Pereboom, Marieke; Becker, Matthijs L; Amenchar, Mostapha; Verweij, Sjoerd L; van, der Hoeven Ruud TM; Mulder, Inge J

Abstract

Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration

Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J

Issue: Jan/Feb 2015 - Volume 19, Number 1

View All Articles in Issue

Page(s): 70-72

Download in electronic PDF format for $75

Abstract

Intravitreal bevacizumab is frequently used off-label for the treatment of neovascular age-related macular degeneration, but there are concerns about the safety of intravitreal administered bevacizumab. It is suggested that repackaging bevacizumab in plastic syringes could affect the safety due to the unknown shelf life of the syringes. In this study, we analyzed the shelf life of the repackaged bevacizumab syringes, stored at 4°C, at certain time intervals. Over the 32 days tested, bevacizumab concentration and the pH were stable. However, the number of particles in the repackaged bevacizumab syringes increased during storage at 4°C and had exceeded the limits for intravitreal injections after 7 days. Since the number of particles seems to be the limitation of the shelf life of repackaged bevacizumab, it is necessary to quantify the number of particles in repackaged bevacizumab. Based on our results the maximum shelf life of repackaged bevacizumab should be 3 days.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jan/Feb 2015 Pg. 70-72	Stability Assessment of Repackaged Bevacizumab for Intravitreal Administration Author(s): Pereboom Marieke, Becker Matthijs L, Amenchar Mostapha, Verweij Sjoerd L, van der Hoeven Ruud TM, Mulder Inge J
Jan/Feb 2008 Pg. 8-14	Intravitreal Bevacizumab for Choroidal Neovascularization in Age-Related Macular Degeneration Author(s): Dib Jean G, Abdulmohsin Saud
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Jul/Aug 2022 Pg. 330-335	Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes Author(s): Bartoll Aaron Puplà, Bellés Medall Maria Dolores, Peñarrocha Josep Edo, Escrig Laura Solaz, Clemente Ruben Eguren, Azuara Julia Bodega, Piqueres Raul Ferrando
Jul/Aug 2011 Pg. 302-307	Treating Inner Ear Disorders with Intratympanic Drug Administration Author(s): McElhiney Linda F
Jan/Feb 2017 Pg. 62	Infliximab 1% Ophthalmic Solution Author(s): Allen Loyd V Jr
May/Jun 2012 Pg. 190-195	I See Colors: Using Vital Dyes in Diagnosing Ophthalmic Disease Author(s): McElhiney Linda F
Sep/Oct 2014 Pg. 418-426	Stability and In Vitro Toxicity of an Infliximab Eye Drop Formulation Author(s): Robert Marie-Claude, Spurr-Michaud Sandra, Frenette Mathieu, Young David, Gipson Ilene K, Dohlman Claes H
Nov/Dec 2022 Pg. 446-466	Compounding with Biotechnology Products, Part 2: Product-specific Considerations Author(s): Allen Loyd V Jr
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
Sep/Oct 2008 Pg. 463-466	Chemical Stability of Admixtures Combining Ziconotide with Fentanyl or Sufentanil During Simulated Intrathecal Administration Author(s): Shields David E, Aclan Jennifer, Szatkowski Aaron
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
Nov/Dec 2016 Pg. 495-500	Basics of Sterile Compounding: Ophthalmic Preparations, Part 2: Suspensions and Ointments Author(s): Allen Loyd V Jr
Nov/Dec 2009 Pg. 506-515	Autologous Eye Drops for the Treatment of Dry Eye and Neurotrophic Keratitis Author(s): Mixon William, Angelle Patricea (Patsy), Chang Richard I
Jul/Aug 2022 Pg. 336-341	Long-term Stability of Epitheliotropic Factors in Frozen Serum Eye Drops Author(s): Sahyoun Jean-Yves, Cloutier Marc, Frenette Mathieu, Robert Marie-Claude
Sep/Oct 2016 Pg. 399-404	Basics of Sterile Compounding: Ophthalmic Preparations, Part 1: Ophthalmic Solutions Author(s): Allen Loyd V Jr
Sep/Oct 2019 Pg. 414-417	Stability of Furosemide 5 mg/mL in Polypropylene Syringes Author(s): van der Schaar JAJ, Grouls R, Franssen EJF, Crul M
Jan/Feb 2013 Pg. 28-38	Treatment Options for Male Hypogonadism Author(s): Biundo Bruce
Jul/Aug 2013 Pg. 270-280	Jet Injection Devices for the Needle-free Administration of Compounds, Vaccines, and Other Agents Author(s): Logomasini Mark A, Stout Richard R, Ron Marcinkoski
Jan/Feb 2024 Pg. 6-14	Treatment Options for Male Hypogonadism Author(s): Biundo Bruce